| 17 | 0 | 8 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：观察益肾排毒汤对脾肾气虚型慢性肾脏病（CKD）3～5期（非透析）老年患者衰弱情况的疗效。方法：将60例CKD 3～5期（非透析）脾肾气虚型老年患者按随机表法分为对照组和观察组各30例。对照组采用常规治疗，观察组予常规治疗联合益肾排毒汤，观察时间为3个月。记录治疗前后血红蛋白（Hb）、血清前白蛋白（PA）、血清白蛋白（ALB）等指标及Fried衰弱表型（FP）量表、微型营养评定简表（MNA-SF）量表评分、肾脏疾病生活质量简表（KDQOL-SFTM1.3）及中医证候积分。综合评价益肾排毒汤对CKD衰弱的疗效。结果：治疗后，两组营养评定、证候积分及疗效、衰弱状态与治疗前比较均有改善（P<0.05）。观察组在营养、中医疗效、衰弱状态、生活质量等改善水平优于对照组，差异有统计学意义（P<0.05）。结论：益肾排毒汤可改善脾肾气虚型CKD3～5期（非透析）老年衰弱患者的衰弱、营养状态及脾肾气虚症状，提升整体生活质量。
Abstract：Objective:To observe the efficacy of Yishen Paidu decoction（益肾排毒汤） on frailty in elderly patients with non-dialysis chronic kidney disease(CKD) stages 3-5 of spleen kidney qi deficiency type. Methods:Sixty elderly patients with non-dialysis CKD stages 3-5 of spleen-kidney qi deficiency type were randomly divided into a control group and an observation group,30 cases in each group. The control group received conventional treatment,while the observation group received conventional treatment combined with Yishen Paidu decoction for three months. Indicators such as serum creatinine(Cr),haemoglobin(Hb),serum prealbumin(PA),and serum albumin(ALB) were recorded before and after treatment. Additionally,scores from the Fried Frailty Phenotype(FP) scale,Mini Nutritional Assessment Short-Form(MNA-SF) scale,Kidney Disease Quality of Life Short Form(KDQOL-SFTM 1.3),and traditional Chinese Medicine(TCM) symptom scores were evaluated to comprehensively assess the efficacy of the decoction on CKD-related frailty. Results:After treatment,both groups showed improvement in nutritional assessment,symptom scores,efficacy,and frailty status compared with before treatment(P<0.05). The observation group showed significantly greater improvements in nutrition,TCM efficacy,frailty status,and quality of life than the control group,with statistical difference(P<0.05). Conclusion:Yishen Paidu decoction effectively ameliorates frailty,improves nutritional status,and alleviates symptoms of spleen kidney qi deficiency in elderly patients with non-dialysis CKD stages 3-5,thereby enhancing overall quality of life.
[1]朱晓亮，张英杰，刘超，等.大黄牡丹汤治疗老年糖尿病足伴慢性肾脏病1~3期临床疗效观察[J].辽宁中医杂志，2024,51(6):107-111.
[2]ZHANG Z,CUI T,CUI M,et al. High prevalence of chronic kidney disease among patients with diabetic foot:a cross-sectional study at a tertiary hospital in China[J]. Nephrology(Carlton),2020,25(2):150-155.
[3]KÖRPINARŞ. A retrospective analysis of microbiologic profile of foot infections in patients with diabetic endstage renal disease[J]. Int J Low Extrem Wounds,2021,20(1):15-21.
[4]GREGG L P,BOSSOLA M,OSTROSKY-FRID M,et al.Fatigue in CKD:epidemiology,pathophysiology,and treatment[J]. Clin J Am Soc Nephro,2021,16(9):1445-1455.
[5]袁弯，张玉莲，张慧瑛，等. 2020版ICFSR老年衰弱指南解读[J].中华现代护理杂志，2021,27(35):4770-4773.
[6]REESE P P,CAPPOLA A R,SHULTS J,et al. Physical performance and frailty in chronic kidney disease[J].Am J Nephrol,2013,38(4):307-315.
[7]WILHELM-LEEN E R,HALL Y N,TAMURA M K,et al. Frailty and chronic kidney disease:the third national health and nutrition evaluation survey[J]. Am J Med,2009,122(7):664-671.
[8]姜德友，周雪明，郭加利.基于古今医案数据分析的虚劳病证治规律研究[J].中华中医药学报，2011,29(1):21-23.
[9]熊明月，王怡.慢性肾衰竭中医证候研究进展[J].中国中西医结合肾病杂志，2021,22(11):1026-1027.
[10]上海市肾内科临床质量控制中心专家组.慢性肾脏病早期筛查、诊断及防治指南（2022年版）[J].中华肾脏病杂志，2022,38(5):12.
[11]郑筱萸.中药新药临床研究指导原则：试行[J].中国医药科技出版社，2002.
[12]何立群.慢性肾衰竭的诊断、辨证分型及疗效评定（试行方案）[J].上海中医药杂志，2006,40(8):8-9.
[13]中华医学会老年医学分会.老年患者衰弱评估与干预中国专家共识[J].中华老年医学杂志，2017,36(3):251-256.
[14]FRIED L P,TANGEN C M,WALSTON J,et al. Frailty in older adults:evidence for a phenotype[J]. J Gerontol Ser A Biol Sci Med Sci,2001,56(3):M146-M157.
[15]RUBENSTEIN L Z,HARKER J O,SALVÀA,et al.Screening for undernutrition in geriatric practice:developing the short-form mini-nutritional assessment(MNASF)[J]. J Gerontol Ser A Biol Sci Med Sci,2001,56(6):M366-M372.
[16]HAYS R D,KALLIEH J D,MAPES D L,et al. Kidney Disease Quality of Life Short Form(KDQOLSFTM),version 1.3:a manual for use and scoring[M].Washington,DC:RAND,1997:110.
[17]岳宗进，刘汝银，于露，等.牛膝多糖通过Notch1通路影响骨髓间充质干细胞向髓核样细胞分化的机制[J].西安交通大学学报（医学版），2022,43(4):600-606.
[18]王华，谭超，王子焱，等.三七总皂苷基于PI3K/Akt/mTOR通路调控自噬和泛素蛋白积累对大鼠肾缺血再灌注损伤的影响[J].现代中西医结合杂志，2023,32(11):1461-1467,1472.
[19]张依轮，刘娜，王立范，等.水蛭对局灶节段性肾小球硬化大鼠肾组织转化生长因子和I型胶原表达的影响[J].中国中医药科技，2021,28(5):726-729.
[20]宋维维，刘晓，李悦，等.大黄干预对慢性肾功能衰竭大鼠模型肠道上皮细胞Claudin-1、Occludin和ZO-1表达的影响[J].新疆医科大学学报，2022,45(11):1241-1247.
[21]贺敏敏，郝怀勇，周珊，等.大黄素联合泼尼松对阿霉素肾病大鼠肾组织转化生长因子-β1表达的研究[J].中华实验外科杂志，2022,39(10):1948-1951.
[22]张惠华，梁亚楠，张蕾.黄芪药学与临床研究现状分析[J].西部中医药，2020,33(12):146-149.
基本信息:
DOI：10.16295/j.cnki.0257-358x.2026.05.011
中图分类号:R277.5
引用信息:
[1]谢嘉好,吴正飞,谢丽萍,等.益肾排毒汤治疗脾肾气虚型慢性肾脏病3～5期（非透析）老年患者衰弱的临床观察[J].山东中医杂志,2026,45(05):513-519.DOI:10.16295/j.cnki.0257-358x.2026.05.011.
基金信息:
广西壮族自治区重点研发计划项目（编号：22JJ A140201）
2026-05-05
2026-05-05